Other Events ·
AbCellera enters preclinical collaboration to develop T-cell engaging antibodies for GI cancers
ABCLAbCellera Biologics Inc.
AbCellera Biologics Inc. announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. The collaboration will utilize AbCellera's antibody discovery engine to uncover optimized development candidates for gastrointestinal (GI) cancers and other solid tumors. AbCellera Biologics Inc. is a biotechnology company focused on antibody discovery and development.